Physician profile
Todd D Martin
NPI 1003926957
$8,333.02
in general payments reported to CMS, 2019-2025
34 companies · $5,545 in 2025
The $5,545 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $224 · 2021: $446 · 2022: $462 · 2023: $532 · 2024: $712 · 2025: $5,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,250 · Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,250.00 |
| Food and Beverage | $1,539.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtual Incision Corporation | $5,282.95 | 2025 | Mira |
| Abbvie INC. | $840.03 | 2019-2025 | |
| Astellas Pharma US INC | $479.74 | 2022-2025 | Veozah, Myrbetriq |
| Coloplast Corp | $342.53 | 2021-2023 | Saffron |
| Bayer Healthcare Pharmaceuticals INC. | $168.39 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $115.82 | 2022-2024 | |
| Meditrina | $107.25 | 2021 | |
| Conmed Corporation | $100.87 | 2024 | Airseal |
| Hologic Sales and Service, LLC | $93.42 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Daiichi Sankyo INC. | $92.69 | 2021-2023 | Injectafer |
| Pfizer INC. | $83.58 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $79.27 | 2019-2023 | Gardasil 9 |
| Allergan, INC. | $50.41 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $45.17 | 2023 | Myfembree |
| Exeltis, USA INC. | $40.46 | 2021-2024 | Slynd |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $39.92 | 2022 | |
| Coopersurgical, INC. | $38.38 | 2020-2025 | Paragard T 380a |
| Therapeuticsmd, INC. | $35.25 | 2020 | |
| Conetic Solutions, INC. | $32.89 | 2025 | |
| Vertical Pharmaceuticals, LLC | $31.60 | 2019-2020 | |
| Ethicon US, LLC | $29.26 | 2021 | |
| Baxter Healthcare | $26.23 | 2024 | Perclot |
| Myriad Women'S Health, INC. | $21.20 | 2023 | Myrisk |
| Biogen, INC. | $19.59 | 2024 | Zurzuvae |
| Davol INC. | $18.66 | 2020 | |
| Avion Pharmaceuticals | $14.55 | 2022 | |
| Amgen INC. | $14.54 | 2019 | |
| Minerva Surgical, INC | $13.50 | 2024 | |
| Evofem Biosciences, INC. | $13.03 | 2022 | |
| Covidien LP | $12.94 | 2019 | |
| Boston Scientific Corporation | $12.81 | 2019 | |
| Organon LLC | $12.48 | 2022 | |
| Lilly USA, LLC | $11.86 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.